Login to Your Account



Malaysia's Duopharma to capitalize on growing SEA biosimilars market

By Carmen Ho
Staff Writer

Monday, March 20, 2017

HONG KONG – Malaysia-based CCM Duopharma Biotech Bhd is positioning itself to capitalize on the growing biosimilars market in Southeast Asia (SEA), following the success of a phase III trial of its erythropoietin (EPO) biosimilar for kidney dialysis. The Kuala Lumpur-based company is set to commence registration of the drug and further strengthen its position in the Malaysian market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription